survival, including that of the American Joint Committee on Cancer, consider only one tumour for every patient and disregard the potential effect of multiple melanomas on outcomes, and this is reflected in the lack of specific management guidelines beyond those dictated for each tumour. [2] [3] [4] We and others have shown that patients with multiple primary invasive melanomas have an increased risk of melanoma death compared with patients with a single melanoma. 5, 6 In contrast, an in situ melanoma in addition to an invasive melanoma does not alter prognosis. 7 This prompted us to examine if the reduced survival of patients with multiple invasive melanomas held across all early invasive melanoma stages (i.e. stages I or II). Details of our data and methods are provided in Appendix S1 (see Supporting Information). A total of 29 393 eligible patients diagnosed with a first primary invasive melanoma of stage I or II between 1995 and 2008 as recorded in the Queensland Cancer Registry were considered. Among these, 27 510 patients had a single primary stage I (S1) or II (S2) melanoma (94%) and 1883 (6%) had two stage I or II melanomas diagnosed within 10 years of each other (Tables S1 and S2 ; see Supporting Information). These patients were grouped into the following categories: S1S1 and S2S2 if they had two stage I or two stage II tumours, respectively; S1S2 if they had a stage I followed by a stage II or S2S1 if tumours occurred in the opposite order. There were approximately 234 500 person-years of follow-up in total, with a median of 9Á5 years per patient, varying from 6Á5 years for the S2 group to 10Á0 years for the S1S1 group. Significant differences were found between the groups in terms of age, sex, body site, morphology and ulceration of both the first and second melanoma (Tables S1 and S2 ; see Supporting Information). By the end of follow-up 6% of patients in the study cohort had died of melanoma and 14% had died of other causes. After making appropriate allowance for time to diagnosis between first and subsequent melanomas by the time-varying covariate method, we analysed melanoma survival in multivariate flexible parametric models. Unadjusted 10-year melanoma-specific survival was 97% for the S1 group and 92% for the S1S1 group (Table 1 and Fig. S1 ; see Supporting Information). After adjustment for sex, age at diagnosis, body site, histopathological subtype, thickness group and ulceration, patients in the in S1S1 group had a 59% increased hazard of melanoma death compared with the S1 group [hazard ratio (HR) 1Á59, P = 0Á022]. Ten-year unadjusted melanoma-specific survival was 71% for the S2 group, 64% for the S2S1 group and 50% for the S1S2 group (Table 1 and Fig. S1 , see Supporting Information). After adjustment, there was no significant difference in 10-year melanoma-specific survival for either the S2S1 group (HR 1Á06, P = 0Á65) or the S1S2 group (HR 1Á32, P = 0Á10) compared with the S2 group. In contrast, the effect on patients with two stage II melanomas (S2S2) within 10 years was to reduce unadjusted survival to 26% (Table 1 and Fig. S1 , see Supporting Information). After adjustment for other prognostic factors, this equated to an almost twofold increased hazard of death from melanoma (HR 1Á92, P < 0Á001) for group S2S2 compared with S2. Table S3 (see Supporting Information) shows the results when all stage I and II melanomas were included in the same model. This analysis demonstrates that all patients with at least one primary stage II melanoma had a higher risk of mortality than those in the S1S1 group. There was little difference when the data were analysed using the delayed entry method, an approach we have used previously (Table S4 ; see Supporting Information). 5 In conclusion, stage I patients diagnosed with a second stage I melanoma, and stage II patients with a second stage II melanoma have a significantly worse outcome compared with those diagnosed with a single primary of equivalent stage. Current guidelines for the clinical management of melanoma do not reflect the peculiar survival of these patients. We therefore propose that health providers take a careful history of earlier melanomas and consider the occurrence of a second primary invasive melanoma within 10 years of the first diagnosis, as an additional criterion of poorer prognosis. In particular, we propose that patients with two stage II melanomas, who fare especially poorly, would benefit from closer monitoring such as is recommended for stage III patients, as well as inclusion in adjuvant therapy trials.
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